Sotera Health Earnings Call Highlights Steady Growth

Sotera Health Company ((SHC)) has held its Q4 earnings call. Read on for the main highlights of the call.

Sotera Health’s latest earnings call struck a cautiously optimistic tone as management highlighted another year of steady growth, margin expansion, and strong cash generation despite several segment‑specific headwinds. Executives framed Nordion’s softness, Nelson Labs’ advisory slowdown, and near‑term margin pressure from new investments as manageable and largely transitory against a backdrop of improving leverage and clear 2026 guidance.

Revenue Growth Holds Steady as Company Scales

Sotera Health reported 2025 revenue of $1.164 billion, up 5.7% year over year and 5.2% on a constant‑currency basis, underscoring resilient demand across its portfolio. Management guided 2026 revenue to a range of $1.233 billion to $1.251 billion, implying 5% to 6.5% constant‑currency growth and signaling confidence in continued steady scaling.

EBITDA Margin Pushes Above 51%

Adjusted EBITDA climbed 8.2% to $593.8 million, or 7.8% on a constant‑currency basis, with margins expanding roughly 118 basis points to 51.0%. For 2026, the company forecast adjusted EBITDA of $632 million to $641 million, a 5.5% to 7% constant‑currency increase and a slight margin uptick to about 51.2% at the midpoint.

Cash Flow Strengthens Balance Sheet and Flexibility

Adjusted free cash flow reached $210 million in 2025, giving Sotera ample room to invest and reduce debt. Net leverage fell to 3.2 times from 3.7 times, while total liquidity stood near $940 million, including $345 million in cash and roughly $600 million of revolver capacity.

Sterigenics Delivers Double‑Digit Top‑Line Growth

Sterigenics stood out with Q4 revenue up 10.6% to $198 million, or 8% in constant currency, aided by 4.3% pricing gains and 3.7% volume and mix benefits. Segment income rose 10.4% to $110 million, and management expects mid‑ to high‑single‑digit constant‑currency growth from Sterigenics in 2026 despite a softer first quarter.

Nelson Labs Improves Margins Despite Advisory Drag

Nelson Labs expanded margins by roughly 312 basis points for the year, signaling progress on efficiency even as select services slowed. In Q4, revenue grew 2.3% to $55 million, essentially flat on a constant‑currency basis, while segment income increased 1.9% to $18 million, leaving profitability roughly stable.

Lower Interest Costs Enhance Earnings Quality

Sotera took advantage of favorable markets by repricing its term loan, cutting borrowing costs by 75 basis points and paying down $86 million of debt. These actions produced about $13 million of annual interest savings, contributing to a $9 million reduction in full‑year interest expense to $156 million.

Operational Wins and Long‑Term Commercial Positioning

Customer satisfaction scores surpassed 80%, and revenue from cross‑business‑unit customers climbed 9%, underscoring the benefits of an integrated offering. Nordion also signed a cobalt development deal with Westinghouse and PSEG and secured a 25‑year Class 1B license renewal for its Ottawa site, bolstering long‑term supply security.

Improved Governance and Larger Public Float

Management pointed to governance upgrades as part of Sotera’s maturation in public markets, including appointing a lead independent director and adding Richard Kyle to the board. The company also increased its public float to roughly 80% of outstanding shares in 2025, enhancing trading liquidity and broadening the investor base.

Nordion Hit by Cobalt Harvest Timing

Nordion’s Q4 revenue fell 12.3% to $50 million as cobalt‑60 harvest timing drove a 15% unfavorable volume and mix impact, highlighting the unit’s inherent lumpiness. Segment income dropped 18.9% to $29 million and margins compressed around 466 basis points to 57.5%, though management framed the decline as timing‑driven rather than structural.

Nelson Labs Faces Advisory Weakness and Soft Q1

Nelson’s Expert Advisory Services remained a pressure point, weighing on overall revenue trends and tempering the otherwise solid lab performance. Looking to 2026, management expects Q1 to be the weakest quarter with low‑to‑mid single‑digit revenue declines versus the prior year and segment income effectively flat on a constant‑currency basis.

Sterigenics Sees Choppy Commercial Volumes

While healthcare volumes were steady, Sterigenics’ commercial business serving food, consumer, and some electronics customers was described as choppy and somewhat shrinking versus earlier periods. The company anticipates a soft start to 2026 for Sterigenics, with mid‑single‑digit growth in Q1 weighed down by planned shutdowns and weather‑related disruptions.

New X‑Ray Facility Brings Near‑Term Margin Dilution Risk

Sotera plans to open a greenfield X‑ray sterilization facility in the second half of 2026, expanding capacity in a key technology area but at the cost of near‑term profitability. Management noted that customer commitments before construction were below the usual 40% utilization threshold, implying a slower ramp and potential margin dilution through 2027.

Higher Depreciation and Capex Pressure Free Cash Flow

Depreciation rose in 2025 and is expected to increase further in 2026 as recent investments come online, weighing on reported earnings. Capital expenditures are projected to climb to $175 million to $225 million in 2026 from $138 million in 2025, which will temporarily constrain free cash flow relative to the underlying run‑rate.

Litigation Overhang and Quarter‑to‑Quarter Volatility

Legal matters remain unresolved, and management acknowledged that ongoing litigation creates a persistent cloud over the stock even without major new timing developments. Executives also reiterated that Q1 is typically the lightest quarter for Sterigenics and Nelson Labs, reinforcing that investors should expect some seasonal volatility in reported results.

Guidance Signals Steady Growth and Deleveraging Ahead

For 2026, Sotera guided revenue to $1.233 billion to $1.251 billion and adjusted EBITDA to $632 million to $641 million, implying modest margin expansion and mid‑single‑digit growth. The outlook assumes pricing near the midpoint of the company’s 3% to 4% range, interest expense of $135 million to $145 million, higher depreciation, capital spending of $175 million to $225 million, continued leverage reduction, and no acquisitions.

Sotera Health’s call painted the picture of a defensive growth story balancing solid fundamentals with manageable risks as it invests for the future. With margins above 51%, strong liquidity, and clear 2026 guidance, the company appears positioned for steady compounding, though investors will need to navigate segment volatility, heavier capex, and the overhang of unresolved litigation in the near term.